Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.
Cencora, Inc. (NYSE: COR) is a premier global pharmaceutical solutions provider committed to enhancing healthcare delivery and improving lives worldwide.
As one of the top three pharmaceutical wholesalers in the United States, Cencora specializes in sourcing and distributing branded, generic, and specialty pharmaceutical products to a diverse range of clients, including retail chains, independent pharmacies, mail-order services, hospital networks, and healthcare providers. In collaboration with McKesson and Cardinal Health, Cencora dominates over 90% of the U.S. pharmaceutical wholesale market.
Beyond its robust domestic operations, Cencora has significantly expanded its international footprint. Notably, the acquisition of Alliance Healthcare in 2021 bolstered its presence in Europe, making it one of the leading drug wholesalers in the region.
Additionally, Cencora offers comprehensive commercialization services for pharmaceutical and medical device manufacturers. Its global specialty drug logistics division, World Courier, is renowned for its precision and reliability. The company also extends its expertise to animal health product distribution through MWI Animal Health.
Cencora's strategic partnerships and innovative solutions drive operational efficiency, cost control, and growth opportunities across the healthcare supply chain.
- Its pharmacy solutions enhance operational efficiency, cost control, growth opportunities, and patient safety.
- Provider solutions focus on improving operational efficiency, financial performance, and quality of care.
- Manufacturer solutions are designed to maximize success at every stage of the product lifecycle.
Recent achievements include a distribution agreement with Sapphiros, enhancing access to COVID-19 Antigen Rapid Tests and future diagnostic technologies in the U.S. market. This partnership is poised to bring innovative diagnostic solutions directly to patients, exemplifying Cencora's commitment to improving accessibility and convenience in healthcare.
Cencora’s mission is driven by a strong sense of purpose: 'We are united in our responsibility to create healthier futures.' Ranked #11 on the Fortune 500 and #24 on the Global Fortune 500, with annual revenues exceeding $250 billion, Cencora’s over 46,000 team members worldwide are dedicated to delivering positive health outcomes through their expertise and collaborative efforts.
Rhea-AI Summary
Cencora, Inc. (COR) has successfully closed a public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034. The company filed a registration statement with the SEC and intends to use the net proceeds to redeem its 3.400% Senior Notes due May 15, 2024, with any remaining funds for general corporate purposes. The joint book-running managers for the offering were BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) has announced the pricing of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 in a public offering. The company plans to use the net proceeds to redeem all of its 3.400% Senior Notes due May 15, 2024, with any remaining net proceeds for general corporate purposes. The joint book-running managers for the offering are BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The offering is expected to close on February 7, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) reported a 15.0% increase in revenue to $72.3 billion for the first quarter of fiscal year 2024. Adjusted diluted EPS also increased by 21.0% to $3.28. The company raised its adjusted diluted EPS guidance range to $13.25 to $13.50 for fiscal 2024. U.S. Healthcare Solutions revenue grew by 15.9%, and International Healthcare Solutions revenue grew by 6.9% in the first quarter. The company's fiscal year 2024 expectations include revenue growth of 10-12% and adjusted diluted earnings per share of $13.25 to $13.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) plans to release its First Quarter Fiscal 2024 results on January 31, 2024, followed by a conference call with Chairman, President & CEO Steven H. Collis and CFO James F. Cleary. The live call will be webcast on investor.cencora.com, with replays available via telephone and webcast. Access codes provided for both live and replay calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
-
News
Rhea-AI Summary
Sapphiros (COR) partners with Cencora, Inc. to distribute COVID-19 Antigen Rapid Tests and future diagnostic technologies, aiming to enhance accessibility and convenience for consumers nationwide. The agreement also includes access to upcoming Sapphiros technologies, such as multiplexed molecular diagnostics platform, rapid lateral flow tests for diseases beyond COVID-19, and the Satio™ blood collection patch in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) announces agreement to repurchase $250 million worth of common stock from Walgreens Boots Alliance Holdings LLC in concurrence with Rule 144 transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
Rhea-AI Summary
Walgreens Boots Alliance (WBA) announced the sale of shares of Cencora, Inc. (COR) through variable prepaid forward transactions, generating $424 million in current proceeds and potentially more at maturity. The company also conducted a concurrent share repurchase by Cencora for $250 million. The proceeds will be used for debt paydown and general corporate purposes, with no dilutive impact on adjusted EPS until the contracts mature in Q4 of fiscal year 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) reported a 12.7% YoY increase in revenue to $68.9 billion for Q4 2023. For the fiscal year 2023, revenue increased 9.9% to $262.2 billion. GAAP diluted EPS for Q4 was $1.72, while adjusted diluted EPS was $2.86. For the fiscal year, GAAP diluted EPS was $8.53 and adjusted diluted EPS was $11.99.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) plans to release Q4 2023 results on November 2, 2023, before the opening of trading on NYSE. Conference call to discuss results at 8:30 a.m. ET. Webcast available on investor.cencora.com. Replays available via telephone and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
Rhea-AI Summary
Cencora, Inc. completes name and stock ticker change, announces $5 million commitment to philanthropy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
FAQ
What is the current stock price of Cencora (COR)?
The current stock price of Cencora (COR) is $227.69 as of December 20, 2024.
What is the market cap of Cencora (COR)?
The market cap of Cencora (COR) is approximately 43.8B.
What does Cencora, Inc. do?
Cencora, Inc. is a leading global pharmaceutical solutions provider, specializing in the sourcing and distribution of branded, generic, and specialty pharmaceuticals.
Who are Cencora's main clients?
Cencora serves retail chains, independent pharmacies, mail-order services, hospital networks, and healthcare providers.
What are some recent achievements of Cencora?
Cencora recently entered into a distribution agreement with Sapphiros to enhance access to COVID-19 Antigen Rapid Tests and future diagnostic technologies in the U.S.
How significant is Cencora in the U.S. pharmaceutical wholesale market?
Cencora, along with McKesson and Cardinal Health, constitutes over 90% of the U.S. pharmaceutical wholesale industry.
What international presence does Cencora have?
Cencora expanded its international presence by acquiring Alliance Healthcare in 2021, becoming a leading drug wholesaler in Europe.
What other services does Cencora provide?
Cencora offers commercialization services for pharmaceutical and medical device manufacturers, global specialty drug logistics, and animal health product distribution.
What is Cencora’s mission?
Cencora's mission is 'We are united in our responsibility to create healthier futures.'
How is Cencora ranked on the Fortune 500?
Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500.
What is the scale of Cencora's operations?
Cencora has over 46,000 employees worldwide and generates more than $250 billion in annual revenue.
What are some key solutions provided by Cencora?
Cencora provides pharmacy solutions for operational efficiency and patient safety, provider solutions for quality care, and manufacturer solutions for product lifecycle success.
Cencora, Inc.
NYSE:COR
COR Rankings
COR Stock Data
43.82B
172.54M
10.72%
93.69%
5.17%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
United States of America
CONSHOHOCKEN